StemCell Therapy

HIGH POINT, N.C., Aug. 14, 2020 Members of the High Point University community frequently conduct, publish and share research and creative works in a variety of ways. Below is a recap of recent research initiatives.

HPU Student, Alumna and Faculty Research Featured in National Scientific Journal

Casey Garr, HPU alumna; Candyce Sturgeon, HPU rising senior; Dr. Veronica Segarra, HPU assistant professor of biology; and Noah Franks, student at Penn Griffin School of the Arts in High Point, North Carolina; recently conducted research that was published in Autophagy, a national scientific journal.

The study, titled, Autophagy as an on-ramp to scientific discovery, examines HPUs Cell Art Collaborative program to gain understanding around how the recruitment of highly creative students into STEM fields through connections to art can be a first step in defining a specialized career path that leads to a valuable and unique contribution to science.

In addition to providing experiential learning opportunities for students at HPU to conduct hands-on research and co-author peer-reviewed articles, the Cell Art Collaborative program encourages students in the local community to explore careers that incorporate both science and art, says Segarra. This initiative continues to facilitate conversations around STEAM-based learning environments for educators to take advantage of a wider range of student talents and interests, preparing them to go forth into society as the creative thinkers and problem solvers the world needs.

HPU Students Research Featured in CBE: Life Sciences Education Journal

Clara Primus, a rising junior majoring in biology and Bonner Leader at HPU, recently collaborated with prominent scientists at the Mayo Clinic, University of California Davis and Northwestern to conduct research that was published in CBE: Life Sciences Education, a quarterly journal published by the American Society for Cell Biology. The article, titled, Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations, examines how scientific societies can contribute to a diverse and inclusive workforce.

The research compares and contrasts the broad approaches that scientific societies within the National Science Foundation-funded Alliance to Catalyze Change for Equity in STEM Success (ACCESS) use to implement and assess their travel award programs for underrepresented minority (URM) trainees. Findings will improve collaboration and better position scientific societies to begin addressing some of these questions and learning from each other.

The recommendations included in this research shed light on how even scientific societies can be allies in furthering inclusion efforts, said Primus. Ive spent nearly two years studying equity and diversity, and I hope that I can take the knowledge Ive learned from all of my research to educate my peers at HPU.

HPU Exercise Science Professor Publishes Statement for the American Heart Association

Dr. Colin Carriker, assistant professor of exercise science in HPUs Congdon School of Health Sciences, recently co-authored an American Heart Association (AHA) scientific statement on medicinal and recreational cannabis use published in Circulation.

The statement critically reviews the use of medicinal and recreational cannabis from a clinical but also a policy and public health perspective by evaluating its safety and efficacy profile, particularly in relation to cardiovascular health. The purpose of this scientific statement was to explore the evidence and science pertaining to medical marijuana, recreational cannabis and cardiovascular health to provide physicians and health care providers with the information available to date. While cannabis may have some therapeutic benefits, these do not appear to be cardiovascular in nature. Health care providers would benefit from increased knowledge, education and training pertaining to various cannabis products and health implications, including recognition that cannabis use may, in fact, exacerbate cardiovascular events or other health problems. In this regard, the negative health implications of cannabis should be formally and consistently emphasized in policy, while aligning with the American Heart Associations commitment to minimizing the smoking and vaping of any products and banning cannabis use for youth.

It was an honor to work alongside such a high-quality team of researchers, says Carriker. I want to especially thank our committee chairs, Dr. Robert L. Page II and Dr. Larry A. Allen, as their extraordinary leadership and organization were integral components in the completion and publication of this AHA scientific statement. We publish these statements to counterbalance and debunk misinformation because the public requires high-quality information about cannabis from reputable organizations such as the American Heart Association.

Carriker is the advocacy ambassador for the American Heart Associations Council on Lifestyle and Cardiometabolic Health and served as a member of the writing committee tasked with writing this AHA Scientific Statement initiated by the AHAs Council on Clinical Cardiology.

Go here to read the rest:
HPU Students, Faculty and Staff Recognized for Research and Innovation - High Point University

STATEMENT BY PREMIER AND MINISTER OF FINANCEHONOURABLE ANDREW A. FAHIE

COVID-19 UPDATE- PHASE II

Friday, 14th August, 2020

I say good day and Gods Blessings to all the people of the Virgin Islands.

We thank the Lord our God for his continued blessings in our lives and in our Territory.

The world continues to grapple with the realities of COVID-19 and the BVI, is not immune.

I appreciate what we continue to do together in our little corner of the world to keep ourselves and each other safe.

So far we have only had nine confirmed cases, including one death with 8 recoveriesmost of the cases being classified as imported or related.

Together, we have been able to stem the tide, but we are not out of the woods.

The problem of COVID-19 has not yet been solved.

It remains a real, deadly, imminent threat to all persons in all countries throughout the world.

We continue to see countries rushing forward with haste to open their borders, refusing to close their borders, or disobeying the recommended hygiene and safety protocols, only for them to hastily retreat as they experience a surge of infections in their population.

Can I tell you that right now, the only measures that are scientifically proven to keep us all safe are social distancing, wearing of appropriate masks or shield, and washing our hands regularly?

These measures are simple for us to do, so let us continue to do them.

In all our actions, your Government is being guided by the law, international protocols and international best practice, with guidance from God Almighty.

In particular, we are being guided by the provisions of the Public Health Ordinance, the Quarantine Act and the Infectious Diseases (Notification) Act, all of which are designed to treat with circumstances such as these, and which prescribes measures that should be taken whenever there is the risk of an outbreak of disease.

All of our precautionary measures for protecting our people from the public health threat of COVID-19 are soundly grounded in the law of the land. And, your Government is being very cautious in dealing with this very fluid situation because another round of lockdown can cripple our economy to the point that we may not be able to bounce back.

Indeed, we understand and empathise with the inconvenience and hardship that COVID-19 is causing to everyone; however we must be cognisant of the double-threat to public health and the economy.

In the BVI, we cannot afford another lockdown. It will not be healthy for our economy, economically, socially and healthwise.

We are not immuned to the trickled effect of COVID-19, which is a health issue.

That is why even with the controlled re-entry of Virgin Islands, Belongers, permanent residence and Naturalisaed Overseas Territories citizens, since 2 June 2020 and the full internal re-opening of businesses, we have been moving cautiously, and in a phased way so that we can realistically manage our environment and surroundings in the midst of the New Regular of living and working with COVID-19.

There have been several views from many quarters trying to pressure the Government to open up quickly and to open up now.

But, I want to echo something that the Chief Medical Officer Dr. Irad Potter said to Members of Cabinet, which I think was the most profound statement that caused all of us to pause, he said and I quote,

We must take into consideration what risk we can take. We must take into consideration what risk we can manage. And, we must take into consideration what we can and cannot allow. End of quote.

Your Government intends to concentrate on the areas that united us as a people because only through unity will we get through this pandemic, successfully.

To date we have been able to manage and monitor the process to the point where on behalf of the Cabinet of the Virgin Islands, I can now announce that we are now moving into Phase two of our Restricted Border Re-opening Plan.

We are satisfied that the different Government agencies have the necessary protocols in place as we advance into Phase two of the restricted border controlled process.

We have had Special meetings of the Cabinet on 13th August and we had to continue the meeting on 14th August. These are not easy decisions, as checks and balances are important.

But having been satisfied that we have properly ventilated and learn from lessons in Phase one to strengthen Phase two, on behalf of Cabinet, I wish to make the following announcements:

1. We decided that the Ministry of Health and Social Development instruct the Attorney General's Chambers to draft a new Immigration and Prohibition Order for the period from 15th August, 2020 to 31st August, 2020;

People of the Virgin Islands Cabinet also advised that the National Security Council should not extend the Curfew Order, which expired on 13th August, 2020, thereby re-opening the Territory internally for 24-hours a day, seven days a week.

However, all businesses and individuals must adhere to all of the approved social measures; and Cabinet also advised that the National Security Council will impose restrictions on the movement of vessels within Territorial waters in a manner prescribed by Order.

Let me say here.

We are not out of the woods with COVID-19. People are coming in, in phase one and two.

We must continue to remain vigilant.

We cannot leave any stone unturned with COVID-19.

That is why the social distancing measures must apply. That is why adherence to the health protocol is a must.

This is our opportunity to test the strength of our system, our protocol, our preventative measures and our commitment to a healthy and safe Virgin Islands.

If we all follow the rules, all will be well.

I want to take this time to remind our bikers those on the scoters, all our bikers, that safe riding save lives. Please ensure that you have a scooter licence, ensure that your motorbikes are licensed and insured, always wear a helmet, know your scooters limits, watch your speed, keep your distance from other vehicles, use both brakes, avoid blind spots, always use signals. Our young generation is important to the future of this Territory. When our youth damage themselves, they damage their future potential in the Virgin Islands. Remember Your Life Matters!

Our responsibility as a Government is to keep the people of the Virgin Islands healthy and safe as much is humanly possible during this COVID-19 era and at all times.

I want to thank everyone who continues to help us to be safe during this COVID-19 era.

My Government, Cabinet Members, National Security Council, Attorney General Chambers, Cabinet Office, all Members of the House of Assembly, the Health Emergency Operations Centre, the Government public officers at varying levels, the Joint Information Cell/Government Information Service, industry partners and members of the public for all coming together and doing their part in this fight against COVID-19.

In these Virgin Islands, each of us has a role to play to help our economy and to keep us safe.

Remember we are all in this together, but I must warn again that we are not out of the woods as far as COVID-19 is concerned.

Remember that COVID-19 is not playing around with us and we must not play around with COVID-19

Now that the curfew is lifted, more than ever, and the borders remain closed, with limited entry, we must hold each other accountable to get through this experience together.

This phase is our greatest test and I know with Gods help we will pass this test.

Please be advised that the main point of entry remains the TB Lettsome International Airport.

So, let us continue to work together in the oneness of purpose.

Remember, God is with us, and He is opening doors for us so that we can have a Virgin Islands that generations would be proud of.

As leader of Government business, we will continue to keep you the people informed of our efforts to continue to combat COVID-19 as this remains a fluid situation. We will continue to make adjustments, so that the people of the Virgin Islands will remain safe while we balance our economy starting with the rebooting and the revitalization of our internal economy.

May God continue to bless these beautiful Virgin Islands and the people of the Virgin Islands.

I thank you.

Read more here:
Statement By Premier Fahie On COVID-19 Update - Phase II - Government of the Virgin Islands

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

- First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone -

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc.(the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated an Expanded Access Program (EAP) to enable doctors across the U.S. to use BeyondSprings late-stage asset, Plinabulin, to prevent cancer patients chemotherapy-induced neutropenia (CIN), both alone and in combination with G-CSFs (the current standard of care), during the COVID-19 pandemic. Dr. Emad Ibrahim enrolled the first patient at Redlands Community Hospital in California on July 28, 2020.

In response to COVID-19, the National Comprehensive Cancer Network (NCCN) recently updated its treatment guidelines for the prophylaxis of CIN, with the objective of preserving hospital and ER resources for COVID-19 patients and maximizing protection for cancer patients against CIN development. This is designed to help necessitate healthcare interactions, and avoidance of hospital / ER visits will also minimize cancer patients risk of contracting COVID-19. In light of these NCCN guideline updates, BeyondSpring initiated an Expanded Access Program to enable the use of Plinabulin by oncologists to better protect cancer patients against CIN with the use of myelosuppressive chemotherapies under the current COVID-19 challenges.

Dr. Emad Ibrahim enrolled the first patient under this EAP at Redlands Community Hospital in California:

The recent updates to the NCCN guidelines aim to protect cancer patients from developing CIN in the most effective way possible and enable the healthcare system to reserve precious resources for COVID-19 patients, said Ramon Mohanlal, BeyondSprings Chief Medical Officer and Executive Vice President, Research and Development. In our CIN studies, Plinabulin, in combination with Pegfilgrastim, provided superior protection against CIN, compared to the standard of care alone. The observation in this first EAP patient who completely avoided Grade 4 CIN when given Plinabulin and Pegfilgrastim is a significant achievement for us. At BeyondSpring, we strive to play our part in serving patients and healthcare providers to the highest degree while working through the many challenges imposed by COVID-19.

Preventing CIN during chemotherapy is extremely important, as this will enable cancer patients to receive the full regimen of chemotherapy and achieve treatment goals. The onset of CIN is the No. 1 reason for treatment modifications, such as downgrading the strength of chemotherapy or stopping chemotherapy altogether. When a patient develops CIN, the treating physician is required to delay the next round of chemotherapy until a patients white blood cell count recovers. These changes can have a profoundly negative impact on patient outcomes.

For more information on BeyondSprings Plinabulin Expanded Access Program, please visit http://www.beyondspringpharma.com/EAP/. Supplies may be limited.

If you are a physician in the U.S. who would like to request Plinabulin EAP access for your patient, please email expandedaccess@beyondspringpharma.com.

About BeyondSpringHeadquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSprings first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen doses decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a pipeline drug, Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed molecular glue that uses the protein degradation pathway.

About PlinabulinPlinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem andCell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

Cautionary Note Regarding Forward-Looking StatementsThis press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media ContactsCaitlin Kasunich / Raquel ConaKCSA Strategic Communications212.896.1241 / 212.896.1276ckasunich@kcsa.com / rcona@kcsa.com

The rest is here:
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the US - BioSpace

Overview

We are a clinical stage biopharmaceutical company focused on the discovery,development and commercialization of drugs for the treatment of cancer. We aredeveloping proprietary drugs independently and through research and developmentcollaborations. Our core objective is to leverage our proprietary phospholipiddrug conjugate (PDC) delivery platform to develop PDCs that are designed tospecifically target cancer cells and deliver improved efficacy and better safetyas a result of fewer off-target effects. Our PDC platform possesses thepotential for the discovery and development of the next generation ofcancer-targeting treatments, and we plan to develop PDCs both independently andthrough research and development collaborations. The COVID-19 pandemic hascreated uncertainties in the expected timelines for clinical stagebiopharmaceutical companies such as us, and because of such uncertainties, it isdifficult for us to accurately predict expected outcomes at this time. We havenot yet experienced any significant impacts as a result of the pandemic and havecontinued to enroll patients in our clinical trials. However, COVID-19 mayimpact our future ability to recruit patients for clinical trials, obtainadequate supply of CLR 131 and obtain additional financing.

Our lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to providetargeted delivery of iodine-131 directly to cancer cells, while limitingexposure to healthy cells. We believe this profile differentiates CLR 131 frommany traditional on-market treatment options. CLR 131 is the company's leadproduct candidate and is currently being evaluated in a Phase 2 study inrelapsed/refractory (r/r) B-cell malignancies, including multiple myeloma (MM),chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia (LPL/WM), marginalzone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-celllymphoma (DLBCL).CLR 131 is also being evaluated in a Phase 1 dose escalationstudy in pediatric solid tumors and lymphoma. The U.S. Food and DrugAdministration ("FDA") granted CLR 131 Fast Track Designation for both r/r MMand r/r DLBCL and Orphan Drug Designation (ODD) of MM, LPL/WM, neuroblastoma,rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. CLR 131 was also grantedRare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma,rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. Most recently, the EuropeanCommission granted an ODD for r/r MM.

Our product pipeline also includes one preclinical PDC chemotherapeutic program(CLR 1900) and several partnered PDC assets. The CLR 1900 Series is beingtargeted for solid tumors with a payload that inhibits mitosis (cell division) avalidated pathway for treating cancers.

We have leveraged our PDC platform to establish four collaborations featuringfive unique payloads and mechanisms of action. Through research and developmentcollaborations, our strategy is to generate near-term capital, supplementinternal resources, gain access to novel molecules or payloads, accelerateproduct candidate development and broaden our proprietary and partnered productpipelines.

Our PDC platform provides selective delivery of a diverse range of oncologicpayloads to cancerous cells, whether a hematologic cancer or solid tumor, aprimary tumor, or a metastatic tumor and cancer stem cells. The PDC platform'smechanism of entry does not rely upon specific cell surface epitopes or antigensas are required by other targeted delivery platforms. Our PDC platform takesadvantage of a metabolic pathway utilized by all tumor cell types in all stagesof the tumor cycle. Tumor cells modify specific regions on the cell surface as aresult of the utilization of this metabolic pathway. Our PDCs bind to theseregions and directly enter the intracellular compartment. This mechanism allowsthe PDC molecules to accumulate over time, which enhances drug efficacy, and toavoid the specialized highly acidic cellular compartment known as lysosomes,which allows a PDC to deliver molecules that previously could not be delivered.Additionally, molecules targeting specific cell surface epitopes face challengesin completely eliminating a tumor because the targeted antigens are limited inthe total number on the cell surface, have longer cycling time frominternalization to being present on the cell surface again and available forbinding and are not present on all of the tumor cells in any cancer. This meansa subpopulation of tumor cells always exist that cannot be targeted by therapiestargeting specific surface epitopes. In addition to the benefits provided by themechanism of entry, PDCs offer the ability to conjugate payload molecules innumerous ways, thereby increasing the types of molecules selectively deliveredvia the PDC.

The PDC platform features include the capacity to link with almost any molecule,provide a significant increase in targeted oncologic payload delivery and theability to target all types of tumor cells. As a result, we believe that we cangenerate PDCs to treat a broad range of cancers with the potential to improvethe therapeutic index of oncologic drug payloads, enhance or maintain efficacywhile also reducing adverse events by minimizing drug delivery to healthy cells,and increasing delivery to cancerous cells and cancer stem cells.

We employ a drug discovery and development approach that allows us toefficiently design, research and advance drug candidates. Our iterative processallows us to rapidly and systematically produce multiple generations ofincrementally improved targeted drug candidates.

In June 2020, the European Medicines Agency (EMA) granted us Small andMedium-Sized Enterprise status by the EMA's Micro, Small and Medium-sizedEnterprise office. SME status allows us to participate in significant financialincentives that include a 90% to 100% EMA fee reduction for scientific advice,clinical study protocol design, endpoints and statistical considerations,quality inspections of facilities and fee waivers for selective EMA pre andpost-authorization regulatory filings, including orphan drug and PRIMEdesignations. We are also eligible to obtain EMA certification of quality andmanufacturing data prior to review of clinical data. Other financial incentivesinclude EMA-provided translational services of all regulatory documents requiredfor market authorization, further reducing the financial burden of the marketauthorization process.

A description of our PDC product candidates follows:

Our lead PDC therapeutic, CLR 131 is a small-molecule, PDC designed to providetargeted delivery of iodine-131 directly to cancer cells, while limitingexposure to healthy cells. We believe this profile differentiates CLR 131 frommany traditional on-market treatments and treatments in development. CLR 131 iscurrently being evaluated in a Phase 2 study in r/r B-cell lymphomas, and twoPhase 1 dose-escalating clinical studies, one in r/r MM and one in r/r pediatricsolid tumors and lymphoma. The initial Investigational New Drug (IND)application was accepted by the FDA in March 2014 with multiple INDs submittedsince that time. Initiated in March 2017, the primary goal of the Phase 2 studyis to assess the compound's efficacy in a broad range of hematologic cancers.The Phase 1 study is designed to assess the compound's safety and tolerabilityin patients with r/r MM (to determine maximum tolerated dose) and was initiatedin April 2015. The FDA previously accepted our IND application for a Phase 1open-label, dose escalating study to evaluate the safety and tolerability of asingle intravenous administration of CLR 131 in up to 30 children andadolescents with cancers including neuroblastoma, sarcomas, lymphomas (includingHodgkin's lymphoma) and malignant brain tumors. This study was initiated duringthe first quarter of 2019. These cancer types were selected for clinical,regulatory and commercial rationales, including the radiosensitive nature andcontinued unmet medical need in the r/r setting, and the rare diseasedeterminations made by the FDA based upon the current definition within theOrphan Drug Act.

In December 2014, the FDA granted ODD for CLR 131 for the treatment of MM.Multiple myeloma is an incurable cancer of the plasma cells and is the secondmost common form of hematologic cancers. In 2018, the FDA granted ODD and RPDDfor CLR 131 for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing'ssarcoma and osteosarcoma. The FDA may award priority review vouchers to sponsorsof rare pediatric disease products that meet its specified criteria. The keycriteria to receiving a priority review voucher is that the disease beingtreated is life-threatening and that it primarily effects individuals under theage of 18. Under this program, a sponsor who receives an approval for a drug orbiologic for a rare pediatric disease can receive a priority review voucher thatcan be redeemed to receive a priority review of a subsequent marketingapplication for a different product. Additionally, these priority reviewvouchers can be exchanged or sold to other companies for them to use thevoucher. In May 2019, the FDA granted Fast Track designation for CLR 131 for thetreatment of multiple myeloma in July 2019 for the treatment of DLBCL, inSeptember, CLR 131 received Orphan Drug Designation from the European Union forMultiple Myeloma, and in January 2020, the FDA granted Orphan Drug Designationfor CLR 131 in lymphoplasmacytic lymphoma (LPL).

Phase 2 Study in Patients with r/r select B-cell Malignancies

In February 2020, we announced positive data from our Phase 2 CLOVER-1 study inpatients with relapsed/refractory B-cell lymphomas. Relapsed/Refractory MM andnon-Hodgkin lymphoma (NHL) patients were treated with three different doses(<50mCi, ~50mCi and ~75mCi total body dose (TBD). The <50mCi total body dose wasa deliberately planned sub-therapeutic dose. CLR 131 achieved the primaryendpoint for the study. Patients with r/r MM who received the highest dose ofCLR 131 showed a 42.8% overall response rate (ORR). Those who received ~50mCiTBD had a 26.3% ORR with a combined rate of 34.5% ORR (n=33) while maintaining awell-tolerated safety profile. Patients in the studies were elderly with amedian age of 70, and heavily pre-treated, with a median of five prior lines oftreatment (range: 3 to 17), which included immunomodulatory drugs, proteasomeinhibitors and CD38 antibodies for the majority of patients. Additionally, amajority of the patients (53%) were quad refractory or greater and 44% of alltreated multiple myeloma patients were triple class refractory. 100% of allevaluable patients (n=43) achieved clinical benefit (primary outcome measure) asdefined by having stable disease or better. 85.7% of multiple myeloma patientsreceiving the higher total body dose levels of CLR 131 experienced tumorreduction. The 75mCi TBD demonstrated positive activity in both high-riskpatients and triple class refractory patients with a 50% and 33% ORR,respectively.

Patients with r/r NHL who received ~50mCi TBD and the ~75mCi TBD had a 42% and43% ORR, respectively and a combined rate of 42%. These patients were alsoheavily pre-treated, having a median of three prior lines of treatment (range, 1to 9) with the majority of patients being refractory to rituximab and/oribrutinib. The patients had a median age of 70 with a range of 51 to 86. Allpatients had bone marrow involvement with an average of 23%. In addition tothese findings, subtype assessments were completed in the r/r B-cell NHLpatients. Patients with DLBCL demonstrated a 30% ORR with one patient achievinga complete response (CR), which continues at nearly 24 months post-treatment.The ORR for CLL/SLL/MZL patients was 33%. Current data from our Phase 2 CLOVER-1clinical study show that four LPL/WM patients demonstrated 100% ORR with onepatient achieving a CR which continues at nearly 27 months post-treatment. Thismay represent an important improvement in the treatment of relapsed/refractoryLPL/WM as we believe no approved or late-stage development treatments forsecond- and third-line patients have reported a CR. LPL/WM is a rare, indolentand incurable form of NHL that is composed of a patient population in need ofnew and better treatment options.

The most frequently reported adverse events in r/r MM patients were cytopenias,which followed a predictable course and timeline. The frequency of adverseevents have not increased as doses were increased and the profile of cytopeniasremains consistent. Importantly, these cytopenias have had a predictable patternto initiation, nadir and recovery and are treatable. The most common grade ?3events at the highest dose (75mCi TBD) were hematologic toxicities includingthrombocytopenia (65%), neutropenia (41%), leukopenia (30%), anemia (24%) andlymphopenia (35%). No patients experienced cardiotoxicities, neurologicaltoxicities, infusion site reactions, peripheral neuropathy, allergic reactions,cytokine release syndrome, keratopathy, renal toxicities, or changes in liverenzymes. The safety and tolerability profile in patients with r/r NHL wassimilar to r/r MM patients except for fewer cytopenias of any grade. Based uponCLR 131 being well tolerated across all dose groups and the observed responserate, especially in difficult to treat patients such as high risk and tripleclass refractory or penta-refractory, and corroborating data showing thepotential to further improve upon current ORRs and durability of thoseresponses, the study has been expanded to test a two-cycle dosing optimizationregimen of CLR 131.

In July 2016, we were awarded a $2,000,000National Cancer Institute (NCI)Fast-Track Small Business Innovation Research grant to further advance theclinical development of CLR 131. The funds are supporting the Phase 2 studyinitiated in March 2017 to define the clinical benefits of CLR 131 in r/r MM andother niche hematologic malignancies with unmet clinical need. These nichehematologic malignancies include Chronic Lymphocytic Leukemia, Small LymphocyticLymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma and DLBCL. Thestudy is being conducted in approximately 10 U.S. cancer centers in patientswith orphan-designated relapse or refractory hematologic cancers. The study'sprimary endpoint is clinical benefit response (CBR), with additional endpointsof ORR, progression free survival (PFS,) median Overall Survival (mOS) and othermarkers of efficacy following a single 25.0 mCi/m2 dose of CLR 131, with theoption for a second 25.0 mCi/m2dose approximately 75-180 days later. Based onthe performance results from Cohort 5 of our Phase 1 study in patients with r/rMM, reviewed below, we have modified the dosing regimen of this study to afractionated dose of 15.625 mCi/m2 administered on day 1 and day 8.

In May 2020, we announced that the FDA granted Fast Track Designation for CLR131 in LPL/WM in patients having received two prior treatment regimens or more.

Phase 1 Study in Patients with r/r Multiple Myeloma

In February 2020, we announced the successful completion of our Phase 1 doseescalation study. Data from the study demonstrated that CLR 131 was safe andtolerated at total body dose of approximately 90mCi in r/r MM. The Phase 1multicenter, open-label, dose-escalation study was designed to evaluate thesafety and tolerability of CLR 131 administered as a 30-minute I.V. infusion,either as a single bolus dose or as two fractionated doses. The r/r multiplemyeloma patients in this study received single cycle doses ranging fromapproximately 20mCi to 90mCi total body dose. To date, an independent DataMonitoring Committee determined that all doses have been safe and well-toleratedby patients.

CLR 131 in combination with dexamethasone is currently under investigation inadult patients with r/r MM. Patients must have been refractory to or relapsedfrom at least one proteasome inhibitor and at least one immunomodulatory agent.The clinical study is a standard three-plus-three dose escalation safety studyto determine the maximum tolerable dose. Multiple myeloma is an incurable cancerof the plasma cells and is the second most common form of hematologic cancers.Secondary objectives include the evaluation of therapeutic activity by assessingsurrogate efficacy markers, which include M protein, free light chain (FLC), PFSand OS. All patients have been heavily pretreated with an average of five priorlines of therapy. CLR 131 was deemed by an Independent Data Monitoring Committee(IDMC) to be safe and tolerable up to its planned maximum single, bolus dose of31.25 mCi/m2. The four single dose cohorts examined were: 12.5 mCi/m2(~25mCiTBD), 18.75 mCi/m2 (~37.5mCi TBD), 25 mCi/m2(~50mCi TBD), and 31.25mCi/m2(~62.5mCi TBD), all in combination with low dose dexamethasone (40 mgweekly). Of the five patients in the first cohort, four achieved stable diseaseand one patient progressed at Day 15 after administration and was taken off thestudy. Of the five patients admitted to the second cohort, all five achievedstable disease however one patient progressed at Day 41 after administration andwas taken off the study. Four patients were enrolled to the third cohort and allachieved stable disease. In September 2017, we announced results for cohort 4,showing that a single infusion up to 30-minutes of 31.25mCi/m2 of CLR 131 wassafe and tolerated by the three patients in the cohort. Additionally, all threepatients experienced CBR with one patient achieving a partial response (PR). Weuse the International Myeloma Working Group (IMWG) definitions of response,which involve monitoring the surrogate markers of efficacy, M protein and FLC.The IMWG defines a PR as a greater than or equal to 50% decrease in FLC levels(for patients in whom M protein is unmeasurable) or 50% or greater decrease in Mprotein. The patient experiencing a PR had an 82% reduction in FLC. This patientdid not produce M protein, had received seven prior lines of treatment includingradiation, stem cell transplantation and multiple triple combination treatmentsincluding one with daratumumab that was not tolerated. One patient experiencingstable disease attained a 44% reduction in M protein. In January 2019, weannounced that the pooled mOS data from the first four cohorts was 22.0 months.In late 2018, we modified this study to evaluate a fractionated dosing strategyto potentially increase efficacy and decrease adverse events.

Following the determination that all prior dosing cohorts were safe andtolerated, we initiated a cohort 7 utilizing a 40mCi/m2 fractionated doseadministered 20mCi/m2 (~40mCi TBD) on days 1 and day 8. Cohort 7 was the highestpre-planned dose cohort and subjects have completed the evaluation period. Finalstudy report and study close-out will be completed later this year.

In May 2019, we announced that the FDA granted Fast Track Designation for CLR131 in fourth line or later r/r MM. CLR 131 is our small-moleculeradiotherapeutic PDC designed to deliver cytotoxic radiation directly andselectively to cancer cells and cancer stem cells. It is currently beingevaluated in our ongoing CLOVER-1 Phase 2 clinical study in patients withrelapsed or refractory multiple myeloma and other select B-cell lymphomas.

Phase 1 Study in r/r Pediatric Patients with select Solid tumors, Lymphomas andMalignant Brain Tumors

In December 2017 the Division of Oncology at the FDA accepted our IND and studydesign for the Phase 1 study of CLR 131 in children and adolescents with selectrare and orphan designated cancers. This study was initiated during the firstquarter of 2019. In December 2017, we filed an IND application for r/r pediatricpatients with select solid tumors, lymphomas and malignant brain tumors. ThePhase 1 clinical study of CLR 131 is an open-label, sequential-group,dose-escalation study evaluating the safety and tolerability of intravenousadministration of CLR 131 in up to 30 children and adolescents with cancersincluding neuroblastoma, sarcomas, lymphomas (including Hodgkin's lymphoma) andmalignant brain tumors. Secondary objectives of the study are to identify therecommended Phase 2 dose of CLR 131 and to determine preliminary antitumoractivity (treatment response) of CLR 131 in children and adolescents. In 2018,the FDA granted OD and RPDD for CLR 131 for the treatment of neuroblastoma,rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. Should any of theseindications reach approval, the RPDD would enable us to receive a priorityreview voucher. Priority review vouchers can be used by the sponsor to receivepriority review for a future New Drug Application ("NDA") or Biologic LicenseApplication ("BLA") submission, which would reduce the FDA review time from 12months to six months. Currently, these vouchers can also be transferred or soldto another entity.

Phase 1 Study in r/r Head and Neck Cancer

In August 2016, the University of Wisconsin Carbone Cancer Center ("UWCCC") wasawarded a five-year Specialized Programs of Research Excellence ("SPORE") grantof $12,000,000 from the National Cancer Institute and the National Institute ofDental and Craniofacial Research to improve treatments and outcomes for head andneck cancer, HNC, patients. HNC is the sixth most common cancer across the worldwith approximately 56,000 new patients diagnosed every year in the U.S. As a keycomponent of this grant, the UWCCC researchers completed testing of CLR 131 invarious animal HNC models and initiated the first human clinical trial enrollingup to 30 patients combining CLR 131 and external beam radiation with recurrentHNC in Q4 2019. This clinical trial was suspended due to the COVID-19 pandemicbut has now been reopened for enrolment.

We believe our PDC platform has potential to provide targeted delivery of adiverse range of oncologic payloads, as exemplified by the product candidateslisted below, that may result in improvements upon current standard of care("SOC") for the treatment of a broad range of human cancers:

Research and development expense. Research and development expense consist ofcosts incurred in identifying, developing and testing, and manufacturing productcandidates, which primarily include salaries and related expenses for personnel,cost of manufacturing materials and contract manufacturing fees paid to contractmanufacturers and contract research organizations, fees paid to medicalinstitutions for clinical trials, and costs to secure intellectual property. TheCompany analyzes its research and development expenses based on four categoriesas follows: clinical project costs, preclinical project costs, manufacturing andrelated costs, and general research and development costs that are not allocatedto the functional project costs, including personnel costs, facility costs,related overhead costs and patent costs.

General and administrative expense. General and administrative expense consistsprimarily of salaries and other related costs for personnel in executive,finance and administrative functions. Other costs include insurance, costs forpublic company activities, investor relations, directors' fees and professionalfees for legal and accounting services.

Three Months Ended June 30, 2020 and 2019

Research and Development. Research and development expense for the three monthsended June 30, 2020 was approximately $2,465,000 compared to approximately$1,810,000 for the three months ended June 30, 2019.

The following table is an approximate comparison summary of research anddevelopment costs for the three months ended June 30, 2020 and June 30, 2019:

General research and development costs 1,018,000 384,000 634,000

The overall increase in research and development expense of $655,000, or 36%,was primarily a result of increased general research and development costsresulting from increased personnel related costs and in clinical project costs.Manufacturing and related costs decreased due to a decrease in materialsproduction processes and related costs. Pre-clinical study costs were relativelyconsistent.

General and administrative. General and administrative expense for the threemonths ended June 30, 2020 was approximately $1,157,000, compared toapproximately $1,391,000 in the three months ended June 30, 2019. The decreaseof approximately $234,000, or 17%, was primarily a result of lower stock-basedcompensation expense.

Six Months Ended June 30, 2020 and 2019

Research and Development. Research and development expense for the six monthsended June 30, 2020 was approximately $5,082,000 compared to approximately$4,118,000 for the six months ended June 30, 2019.

The following table is a comparison summary of research and development costsfor the six months ended June 30, 2020 and June 30, 2019:

General research and development costs 1,779,000 914,000 865,000

The overall increase in research and development expense of approximately$964,000, or 23%, was primarily a result of increased general research anddevelopment costs resulting from increased personnel related costs and inclinical project costs. Manufacturing and related costs decreased due to adecrease in materials production processes and related costs. Pre-clinical studycosts were relatively consistent.

General and Administrative. General and administrative expense for the sixmonths ended June 30, 2020 was approximately $2,499,000, compared toapproximately $2,712,000 in the six months ended June 30, 2019. The decrease ofapproximately $213,000, or 8%, was primarily a result of lower stock-basedcompensation expense.

Liquidity and Capital Resources

As of June 30, 2020, we had cash and cash equivalents of approximately$22,450,000 compared to $10,615,000 as of December 31, 2019. This increase wasdue primarily to the approximately $18,300,000 of net proceeds received inconnection with the June 5, 2020 public offering. Net cash used in operatingactivities during the six months ended June 30, 2020 was approximately$6,562,000.

Our cash requirements have historically been for our research and developmentactivities, finance and administrative costs, capital expenditures and overallworking capital. We have experienced negative operating cash flows sinceinception and have funded our operations primarily from sales of common stockand other securities. As of June 30, 2020, we had an accumulated deficit ofapproximately $119,251,000.

We believe that the cash balance is adequate to fund our basic budgetedoperations for at least 12 months from the filing of these financial statements.However, our future results of operations involve significant risks anduncertainties. Our ability to execute our operating plan beyond that timedepends on our ability to obtain additional funding via the sale of equityand/or debt securities, a strategic transaction or otherwise. We plan toactively pursue all available financing alternatives; however, there can be noassurance that we will obtain the necessary funding. Other than theuncertainties regarding our ability to obtain additional funding, there arecurrently no known trends, demands, commitments, events or uncertainties thatare likely to materially affect our liquidity. Because we have had recurringlosses and negative cash flows from operating activities, and in light of ourexpected expenditures, the report of our independent auditors with respect tothe financial statements as of December 31, 2019 and for the year ended December31, 2019 contains an explanatory paragraph as to the potential inability tocontinue as a going concern. This opinion indicated at that time, thatsubstantial doubt existed regarding our ability to remain in business.

Edgar Online, source Glimpses

Go here to see the original:
CELLECTAR BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

The glow

When it comes to supplements, are we too reliant on these miracle capsules for skin-deep beauty? We look at a 360-degree approach instead.

Over the years of curating our routines and discovering hero products that deliver exactly what we need, one thing we all have come to realise is that beauty isnt only skin-deep. There has been an evolution of products on the market that promise to nourish our complexion, and they are not just the formulas you apply on the surface. Many well-known brands have extended their skincare lines beyond topical products by introducing supplements that help tackle concerns from the inside. See it as a 360-degree approach to your daily routine.

The glow heroes:C.E.O. Glow Vitamin C + Turmeric Face Oil Dhs155 Sunday Riley at Sephora; Charlottes Magic Serum Crystal Elixir Dhs285 Charlotte Tilbury

Some specialists believe that topical products only address around 20 per cent of skin issues, which naturally forces us to look to supplements as well as personal habits. Skin is the largest organ of our body. It is meant to protect us, but it is also a mirror a mirror that reflects our health and the faults in the body, Zuzana Hrdinova, a Lifestyle Consultant and Health Coach, explains.

Despite the nutritional supplement market being a multi-billion-dollar industry, the data to support the use of most of these products is poor. There is very little evidence that any supplement or a multivitamin can reverse the course of a disease or play a role in our skin health, she adds.

Shirley DSouza, a Certified Ketogenic & Primal living coach, agrees that there are a lot of decoy supplements out there in the market, especially when claiming a whole list of benefits, but does believe some supplements can be beneficial in replenishing the nutrients that are lost through the agricultural process.

The glow heroes:Integrative Beauty Dhs300 SkinFusion; Skin Food + Prebiotic Dhs184 The Nue Co. at net-a-porter.com

Supplements may be useful for people who are unable to get adequate nutrition from diet alone, adds health coach, Sheetal Ramchandani. For example, it is recommended that vegans take a supplement of vitamin B12 since it isnt adequately available in plant foods and some specific conditions, like gastrointestinal issues that can affect nutrient absorption, call for more than high nutrition and require extra support that supplements can provide.

Zinc is one of the widely recommended supplements that support the immune system, while Omega 3 repairs the skin barrier. Iron can also be extremely beneficial, especially for those prone to eczema or psoriasis. But like with anything, seeking professional advice is the best way for you to know for sure that what you are taking is beneficial, as Hrdinova points out: If you take calcium, magnesium or zinc, but you are deficient in Vitamin D, you will not be absorbing those minerals and hence you will not see any results.

Vitamin C and E are emerging as skincare heroes among the beauty insiders as they are seen as powerful antioxidants. Collagen supplements are also on the rise. As we age, we produce less collagen that results in wrinkles and loss of skin elasticity. It is still hard to judge whether the collagen you ingest will have the same properties when it reaches your skin as the digestion process breaks it down, so perhaps its more beneficial to look at products that encourage collagen production. Chicken soup, for example, is rich in amino acids which encourages our bodies to produce collagen. One big change I would add to a diet is bone broth chicken or beef which is full of collagen but more importantly full of electrolytes and has properties that help, our gut health a lot more. Our gut health is important as it is our main communication to the brain, hormones and nerves, DSouza reveals.

The glow heroes:Skinesis Stem Cell Collagen Activator Dhs685 Sarah Chapman at Harvey Nichols Dubai; Super Seed Supplement Dhs162 Votary

It appears that all of our supplement trails lead us back to something we can easily change our diet. There are certain nutrients that help us to get the look of glowing, healthier skin and slow down the ageing process, Hrdinova explains. Essentials are vitamin C, E, A, antioxidants, essential fatty acids, copper, zinc, selenium, but also vitamin B and iron. All these nutrients are available in a balanced diet. My advice for anybody who wants to have smoother and clearer complexion and glossy, silky hair is to eat healthy food including lots of fruit and vegetables, drink sufficient water, exercise frequently, get out in the fresh air, get proper rest and learn to manage your stress levels.

DSouza also champions a healthy lifestyle, promoting a balanced diet and cutting down on junk food. Cucumber and kale added to our diet has properties of naturally hydrating our skin, the nutrient silica is a trace mineral found in high levels inside cucumbers, she explains. Silica contributes to the growth and maintenance of connective tissue throughout your body.

We need to limit eating things in plastic or packets with long shelf life and eat more natural basic ingredients, she continues. If you cannot pronounce the additive or do not know the added preservative do not eat it.

Hrdinova echoes this saying, Excessive consumption of refined sugars and artificial sweetener and trans fats (fried food) can cause inflammation which may lead to a breakdown in collagen and elastin and have a negative impact on the skins strength and elasticity. Too much of caffeine from coffee or energy drinks have an impact on the hormonal levels in our body and may lead to breakouts of acne.

The only additional supplement DSouza would add for a glowing complexion is a probiotic at least with a minimum of 1 billion colony forming units and containing either genus Lactobacillus, Bifidobacterium or Saccharomyces boulardii.

Looking at the busy skincare industry promising a miracle solution with every new launch, it is easy to become overwhelmed at the options that are before you. The bottom line, take a closer look at your diet, seek advice if you want to introduce supplements, and continue to enhance your skincare routine. A glowing and healthy complexion requires attention from all angles, especially if you want to achieve long-lasting results.

Images: Supplied

Read more:
A 360-degree approach to getting the perfect glowy skin this summer - Emirates Woman

A HIV-positive man in remission may be the first patient effectively cured of the illness without needing a bone marrow transplant, researchers said Tuesday in a potential breakthrough.

HIV affects tens of millions of people globally and while the disease is no longer the automatic death sentence it once was, patients need to take medication for life.

In recent years two men -- known as the "Berlin" and "London" patients -- appear to have been cured of the disease after undergoing high-risk stem cell bone marrow transplants to treat cancer.

Now an international team of researchers believe they may have a third patient who no longer shows sign of infection after undergoing a different medicine regimen.

The patient, a 34-year-old Brazilian who has not been named, was diagnosed with HIV in 2012.

As part of the study, he was given several potent antiviral drugs, including maraviroc and dolutegravir, to see if they could help him rid the virus from his body.

He has now gone more than 57 weeks with no HIV treatment and he continues to test negative for HIV antibodies.

Ricardo Diaz, an infectious diseases expert at the University of Sao Paulo, said the patient could be considered to be free of the disease.

"The significance for me is that we had a patient that was on treatment and he is now controlling the virus without treatment," he told AFP.

"We're not able to detect the virus and he's losing the specific response to the virus -- if you don't have antibodies then you don't have antigens."

Diaz's findings were released as part of the first-ever all-virtual International AIDS Conference, held online this year due to the coronavirus pandemic.

The United Nations said Monday that 1.7 million people contracted HIV last year and there are now more than 40 million people living with it.

Diaz said his team's treatment method, which needs further research, was a more ethical avenue for gravely ill HIV sufferers than the bone-marrow transplant route.

"They come with a high mortality rate, there have been a series of patients who have either died from the procedures or it didn't work," he said.

Sharon Lewin, co-Chair of the International AIDS Society Initiative Towards an HIV Cure and director of the Doherty Institute for Infection and Immunity in Melbourne, said Diaz's findings were "very interesting".

She struck a note of caution however, due to the study's limitations.

She noted that the Brazil patients' antibody test had gotten weaker over time -- suggesting a diminishing immune response.

"This is very unusual to see in someone off antivirals," she said. "The Berlin and London Patients may be the only exceptions. This very provocative data needs more in-depth analysis."

See the original post:
HIV patient 'first in remission' without transplant - Japan Today

A new intelligence report Circulating Tumor Cells (CTC) Market Was recently added to Circulating Tumor Cells (CTC) Market Research collection of top-line market study reports. International Circulating Tumor Cells (CTC) Market report is a meticulous all-inclusive analysis of this market that provides access to direct firsthand insights on the growth trail of market at near term and long term. On the grounds of factual advice sourced from authentic industry pros and extensive primary business study, the report offers insights about the historical growth pattern of Circulating Tumor Cells (CTC) Market and present market situation. It then provides brief and long-term market growth projections.

Projections are only based on the comprehensive analysis of key Market dynamics that are expected to influence Circulating Tumor Cells (CTC) Market performance and also their seriousness of impacting market growth within the span of assessment interval.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2638984&source=atm

In addition to evaluation of dynamics, the report supplies In-depth examination of key business trends that are anticipated to behave more prominently in global Circulating Tumor Cells (CTC) Market. The study also provides valued information concerning the present and upcoming growth opportunities in Circulating Tumor Cells (CTC) Market the important players and new market entrants can capitalize on.

Competitive Businesses And manufacturers in global market

The key players covered in this studyAdnaGenApocellBiocepCanopus BioscienceCreatv MicrotechIkonisysIV DiagnosticsMiltenyi BiotechNanostring TechnologiesRarecells DiagnosticsVitatex

Market segment by Type, the product can be split intoEx-Vivo Positive SelectionIn-Vivo Positive SelectionNegative SelectionMicrochips & Single Spiral Micro ChannelMarket segment by Application, split intoTumorigenesis ResearchEmt Biomarkers DevelopmentCancer Stem Cell ResearchOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Circulating Tumor Cells (CTC) status, future forecast, growth opportunity, key market and key players.To present the Circulating Tumor Cells (CTC) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Circulating Tumor Cells (CTC) are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2638984&source=atm

Opportunity assessment offered in this Circulating Tumor Cells (CTC) Market report Is important in terms of understanding the lucrative regions of investment, which prove to be the actionable insights for major market players, providers, distributors, and other stakeholders in Circulating Tumor Cells (CTC) Market.

In-depth global Circulating Tumor Cells (CTC) Market taxonomy presented in this Report offers detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional evaluation of global Circulating Tumor Cells (CTC) Market divides global market landscape into essential geographies.

Regional prognosis and country-wise analysis of Circulating Tumor Cells (CTC) Market Allows for the analysis of multi-faceted operation of marketplace in all of the crucial markets. This information intends to provide a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Taxonomy and geographic analysis of the international Circulating Tumor Cells (CTC) Market enables readers to see profits in present chances and catch upcoming growth chances even until they approach the market location. The analysis given in report is only meant to unroll the economic, societal, regulatory and political situations of this market specific to each area and country, which could help potential market entrants in Circulating Tumor Cells (CTC) Market landscape to comprehend the nitty-gritty of target market areas and invent their plans accordingly.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2638984&licType=S&source=atm

Circulating Tumor Cells (CTC) Market Table of Contents

Originally posted here:
Circulating Tumor Cells (CTC) Market Business Overview, Revenue, Price and Gross Margin, Product Specifications, Forecast 2032 Bulletin Line -...

Global Circulating Tumor Cells Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Circulating Tumor Cells Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-circulating-tumor-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146935#request_sample

Major Players:

BioceptAdnagenNanostring TechnologiesApoCellCanopus BioscienceMiltenyi BiotechVitatexIkonisysRarecells DiagnosticsCreatv MicrotechIV Diagnostics

Global Circulating Tumor Cells Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Ex-Vivo Positive SelectionIn-Vivo Positive SelectionNegative SelectionMicrochips & Single Spiral Micro Channel

Segmentation by Application:

Tumorigenesis ResearchEMT Biomarkers DevelopmentCancer Stem Cell ResearchOthers

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/146935

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-circulating-tumor-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146935#inquiry_before_buying

Table of Content:

The Global Circulating Tumor Cells Market

Chapter 1: Circulating Tumor Cells Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Circulating Tumor Cells Market Competition by Manufacturers

Chapter 3: Circulating Tumor Cells Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Circulating Tumor Cells Market Effect Factors Analysis

Chapter 11: Circulating Tumor Cells Market Forecast

Chapter 12: Conclusion of Circulating Tumor Cells Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-circulating-tumor-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146935#table_of_contents

Excerpt from:
Global Circulating Tumor Cells Market Analysis and Forecast 2027- including drivers, constraints, intimidation, challenges, opportunities, and...

TheS&P/ASX 200 Index(ASX: XJO) was out of form last week and dropped notably lower. The benchmark index fell a disappointing 2.3% to 5,919.2 points.

Not all shares dropped lower with the market last week. Heres why these ASX 200 shares were flying high:

The Netwealth Group Ltd (ASX: NWL) share price was the best performer on the ASX with a 18.4% gain. Investors were buying the investment platform providers shares last week following the release of its fourth quarter update. At the end of the quarter, Netwealths funds under administration (FUA) had climbed to a sizeable $31.5 billion. This means the company grew its FUA by $8.2 billion or 35% during FY 2020. This includes a negative market movement of $0.9 billion for the 12 months.

The Perseus Mining Limited (ASX: PRU) share price was an impressive performer last week with a 12.3% gain. The catalyst for this strong gain was another rise in the gold price. Traders were fighting to get hold of the precious metal after coronavirus cases spiked globally. Demand was so strong the gold price broke through the US$1,800 an ounce mark and hit a nine-year high. For the same reason, St Barbara Ltd (ASX: SBM) and Gold Road Resources Ltd (ASX: GOR) shares stormed 10.3% and 9.3% higher, respectively.

The Mesoblast limited (ASX: MSB) share price was on form and jumped 8.9% last week. Investors were buying the allogeneic cellular medicines developers shares after it provided an update on its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. That update revealed that the product has been given an expanded access protocol for compassionate use in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome.

The Megaport Ltd (ASX: MP1) share price wasnt far behind with a gain of 8.4%. This was despite there being no news out of the global leading provider of elastic interconnection services. However, with the pandemic accelerating the shift to the cloud, investors appear confident that Megaport will be experiencing very strong demand for its services.

We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

See the 5 stocks

*Extreme Opportunities returns as of June 5th 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MEGAPORT FPO. The Motley Fool Australia owns shares of Netwealth. The Motley Fool Australia has recommended MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

See the article here:
These were the best performing ASX 200 shares last week - Motley Fool Australia

Side effects can happen with any type of treatment, but everyones experience is different. Some people may have many side effects. Others have fewer.

Side effects can happen any time during, immediately after or days to months after a stem cell transplant. Short-term (acute) side effects generally develop during the first 100 days after a stem cell transplant. Long-term (chronic) side effects generally develop 100 or more days after the transplant. Most side effects go away on their own or can be treated, but some side effects can last a long time or become permanent.

Side effects of a stem cell transplant will depend mainly on:

A stem cell transplant is very complex. It can take 6 to 12 months or longer for your blood counts to be back to normal and your immune system to work well. Side effects of a stem cell transplant can be very serious or even life-threatening. The healthcare team will watch you closely during this time. They will take measures to prevent side effects and will quickly deal with any side effects that develop.

Children usually have less severe side effects than adults and will often recover from them faster. But its hard to say exactly which side effects a child will have, how long they will last and when the child will recover.

Many common side effects, such as nausea, vomiting, fatigue and temporary hair loss, are from the chemotherapy or radiation therapy given before the transplant. Other side effects are related to the stem cell transplant.

You will have low blood cells counts after a stem cell transplant. It takes time for stem cells to make their way to the bone marrow and start making new blood cells (called engraftment).

You will have daily blood tests to check the number of different types of blood cells until doctors see a steady increase in blood cell counts.

Infection is one of the most common early side effects of a stem cell transplant. It happens because the white blood cell count is very low and the immune system is weak. Bacterial infections are most common. Viral or fungal infections can also happen.

The risk of infection for all types of transplant is high until the bone marrow starts to make white blood cells. The risk is highest after an allogeneic transplant because you may be taking medicines to suppress the immune system to prevent graft-versus-host disease (GVHD).

Infection can also happen a long time after a stem cell transplant. The risk of late infection depends on how quickly your immune system recovers, whether you have GVHD and if you are taking medicines to suppress your immune system.

Fever is often the first sign of infection. Even if there is no sign of infection, most people are given medicines to prevent infection until their white blood cell counts start to rise. Doctors may also prescribe a colony-stimulating factor (CSF) such as filgrastim (Neupogen) following a stem cell transplant to help lower the risk of infection and speed up the process of making new blood cells.

Bleeding can happen after a stem cell transplant because the platelet count is very low and it reduces the bloods ability to clot. Some people get serious bleeding problems (hemorrhage). If the red blood cell count is too low, it can lead to anemia. You may need platelet transfusions until the transplanted stem cells start to work, especially during the first month after the transplant.

Anemia is a low red blood cell count and a lower concentration of hemoglobin in blood cells. Hemoglobin is the part of the red blood cell that carries oxygen. When hemoglobin levels are low, body tissues dont get enough oxygen and cant work properly. Colony-stimulating factors, such as epoetin alfa (Eprex, erythropoietin) or darbepoetin (Aranesp), may be given to help increase red blood cell counts. If the red blood cell count is too low, blood transfusions may be needed.

Graft-versus-host disease (GVHD) might happen after an allogeneic stem cell transplant. Healthy stem cells from the donor (person who gives the stem cells) attack the cells of the recipient (person receiving the stem cells). The cells from the donor see the recipients cells as foreign and start to destroy them. GVHD can permanently damage an organ.

You may have to take immune-suppressing drugs for months or years after an allogeneic transplant to prevent or treat GVHD.

Veno-occlusive disease (VOD) happens when small blood vessels that lead to the liver become blocked. VOD is more common after an allogeneic transplant. It can develop in the first few weeks after a stem cell transplant and can lead to liver damage.

Symptoms include jaundice, tenderness of the liver and fluid buildup in the abdomen. Medicine may be used to prevent or treat VOD.

Digestive problems happen because tissues in the mouth, stomach and intestines are sensitive to the chemotherapy drugs given before the transplant. Digestive problems can also be caused by infection, GVHD or side effects of medicines.

Digestive system problems include:

Your healthcare team may give you special mouthwashes or lozenges and pain medicines for a sore mouth. They will also talk to you about good mouth care during and after treatment. You may have medicines to control diarrhea, nausea and vomiting.

If you have trouble eating, the healthcare team may suggest that you eat small meals and snacks instead of big meals or take food supplements.

For severe eating problems, you may be given nutrition through the central venous catheter (tube). This is called parenteral nutrition or total parenteral nutrition (TPN).

The therapy given before the transplant and GVHD can cause skin problems. This side effect is common when certain chemotherapy drugs and total body irradiation (TBI) are used. Skin problems include rashes, itching, blisters and peeling skin. The healthcare team will tell you how to care for your skin. Medicated creams or ointments and other medicines may be given to help manage skin problems.

Temporary hair loss can also happen after therapies given before the transplant. Hair loss is rarely permanent. It usually grows back within 3 to 6 months after the transplant.

Pain occurs when tissues or nerves are inflamed. Pain can be caused by the chemotherapy and radiation therapy given before the transplant and by infection, medicine, mouth sores and skin problems.

Pain medicines and other therapies, such as relaxation or visualization, are used to help relieve pain. The healthcare team will help prevent and manage your pain.

Kidney problems can happen when the kidneys are damaged by chemotherapy drugs given before the transplant, by antibiotic therapy or by medicine used to suppress the immune system. Sometimes kidney problems become so serious that they can lead to kidney failure, which is a long-term problem.

To prevent kidney problems after a transplant or to treat kidney problems that happen, your healthcare team may limit the amount of fluids you drink and change some of your medicines. The healthcare team will closely check the amount of fluids you take in and put out as urine. They will take measures to prevent and reduce damage to the kidneys as much as possible during treatment.

Lung problems can happen when the lungs are damaged by the chemotherapy and radiation treatments given before the transplant, by infection or by drinking too much fluid after the transplant. Lung problems are common in people with GVHD and include the following:

The healthcare team will check you with chest x-rays and lung function tests. You may be given medicines to prevent infection after the transplant or to treat lung problems if they develop.

Heart problems are not common after a stem cell transplant but they can happen. Certain chemotherapy drugs given before the transplant can cause the heart not to work as well. They can also cause the tissue around the heart to become inflamed (called pericarditis).

A multigated acquisition (MUGA) scan to check how well your heart is working and assess any damage to the heart muscle is often done before chemotherapy is given. Chemotherapy drugs that are less damaging to the heart may be used before a stem cell transplant. Medicines can be used to treat heart problems that develop after a transplant.

The central nervous system (CNS) is made up of the brain and spinal cord. Brain tissue can be damaged by radiation treatments given before a stem cell transplant, by chronic GVHD, by infection or by a return of the cancer.

CNS problems can develop months or years after a stem cell transplant. CNS problems can include damage to the brain that results in problems with mental (cognitive) function. Other CNS problems include:

Report changes in your mental function to the healthcare team. You may see a neurologist and have therapy to help with these changes.

Eye problems usually develop a year after a stem cell transplant, but they can also happen several years later. Eye problems can happen if total body irradiation is given before a stem cell transplant. Chemotherapy and steroids may also increase the chance of developing eye problems.

The most common eye problem is cataracts. A cataract clouds the lens of the eye and can cause vision loss. You will be encouraged to have regular eye exams and report any vision changes. Cataracts are removed with surgery.

Another eye problem is ocular GVHD. It causes eye dryness with a gritty or sandy feeling. Ocular GVHD is treated with eye drops for comfort and to help the eyes produce tears. You may also be given medicine to prevent infection.

Bladder problems can happen when chemotherapy and radiation treatments given before the transplant scar the bladder wall. This can lead to frequent urination, blood in the urine and bladder spasms. Drugs that suppress the immune system can cause recurring bladder infections. You may be given medicines to decrease bladder spasms and treat infections. You will be encouraged to drink extra fluids.

The risk of developing thyroid problems is quite high when total body irradiation is used before a stem cell transplant. Hypothyroidism is the most common thyroid problem. This is where the thyroid does not make enough thyroid hormone. Symptoms of hypothyroidism include fatigue, weight gain, hair loss, brittle nails, dry skin and feeling cold.

For adults, thyroid function may be checked each year after a stem cell transplant. Some people may need thyroid hormone replacement therapy if the thyroid doesnt make enough thyroid hormone.

If children do not have enough thyroid hormone, it slows their physical and mental development. It usually develops a few years after treatment and can become a long-term problem. The thyroid function will be checked often. Some children may need thyroid hormone replacement every day to regulate the thyroid gland.

In children, total body irradiation can cause long-term developmental and growth delays. This can happen because radiation to the head affects the hypothalamus in the brain. The hypothalamus controls the release of growth hormones. Low levels of growth hormones will result in shorter height, shortened limbs and less overall physical development. Steroid medicines and GVHD can also affect growth. Treatment with growth hormones may be needed.

Fertility problems can happen because of chemotherapy or radiation therapy given before a stem cell transplant. When the reproductive organs (gonads) stop working, it is called gonadal dysfunction.

Children receiving treatment, especially those close to or during puberty, have the greatest chance of having long-term or permanent gonadal dysfunction, called gonadal failure. Children treated before puberty have fewer problems with reproductive organ function and fertility.

Most women who have a stem cell transplant will experience treatment-induced menopause. Men and women may regain gonadal functioning and fertility, but gonadal dysfunction may become permanent and cause infertility.

Hormone replacement therapy may be given for gonadal dysfunction.

Talk to your healthcare team about fertility problems. They can suggest ways to help women cope with symptoms of menopause. They can also provide information about ways you can preserve your fertility. Women may choose to freeze and store fertilized eggs (embryos) to be implanted after the transplant and recovery. Men may choose to freeze and store their sperm for future use.

Liver problems that can develop include veno-occlusive disease (VOD), graft-versus-host disease, infection or damage due to the medicines given before the transplant. Treatment is supportive and includes medicines for VOD, infection and pain. If kidney function is also affected, treatment includes limiting the amount of fluids you drink and changing some medicines.

Graft-versus-host disease is the most common cause of late oral and dental problems. Symptoms range from mild tenderness of the mouth, throat, esophagus and stomach to severe pain. Decreased saliva production results in tooth decay (cavities). Infections can also contribute to oral problems.

Mouth rinses, steroid dental pastes and medicines are used to treat oral and dental problems. You will be taught about careful and thorough care of your teeth and mouth. You will be encouraged to have regular visits to your dentist. You may be given fluoride treatments to help prevent cavities.

Primary graft failure means that transplanted stem cells have not started making new blood cells in the first 3 to 4 weeks after the transplant. Treatment for primary graft failure is a second stem cell transplant.

Secondary graft failure happens after new blood cells start appearing. Treatment includes a combination of growth factors such as erythropoietin and G-CSF. If an allogeneic transplant has been done, medicines to suppress the immune system are stopped. Lymphocytes from the donor or a second transplant may be needed.

Graft rejection (stem cell rejection) happens if the body rejects the transplanted stem cells. This is more common in allogeneic transplants, especially when the donor is unrelated or less well matched. Graft rejection may be treated with growth factors. Sometimes a second transplant can be done.

Osteoporosis is a loss of bone density. It makes the bones weak. It can develop late after a stem cell transplant because of medicines, gonadal dysfunction or lack of physical activity. Treatment includes taking extra vitamin D and calcium. Medicines called bisphosphonates may be given for severe osteoporosis. Women who have treatment-induced menopause may consider hormone replacement therapy to keep bones from becoming weaker.

Quality of life can be greatly affected by the problems caused by the transplant, the long-term side effects and the medicines needed to treat some of the long-term effects.

Some factors that can affect quality of life include depression, anxiety and changes in body image. Relationships with your family and friends can be affected by the stress of having cancer and getting a stem cell transplant for cancer. Also, the duration of the transplant and the long time it takes to recover may make you feel socially isolated.

Transplant centres and hospitals often have plans of care that will improve quality of life, including education for you and your family. Counselling about your work, rehabilitation programs, support groups and psychological counselling may help decrease the negative effects on quality of life.

Other cancers can develop because of the amount of chemotherapy and radiation therapy given before the transplant.

The chance of getting a second cancer increases over time. Doctors will check for a second cancer at all follow-up appointments.

Read the rest here:
Side effects of a stem cell transplant - Canadian Cancer ...

Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells dont have estrogen or progesterone receptors and also dont make too much of the protein called HER2. (The cells test "negative" on all 3 tests.) These cancers tend to be more common in women younger than age 40, who are African-American, or who have a BRCA1 mutation.

Triple-negative breast cancer differs from other types of invasive breast cancer in that they grow and spread faster, have limited treatment options, and a worse prognosis (outcome).

Triple-negative breast cancer can have the same signs and symptomsas other common types of breast cancer.

Once a breast cancer diagnosis has been made using imaging tests and a biopsy, the cancer cells will be checked for certain features. If the cells do not have estrogen or progesterone receptors, and also do not make too much of the HER2 protein, the cancer is considered to be triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time its found and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They cant tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they cant predict what will happen in any particular persons case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you, as he or she is familiar with your situation.

A relative survival rate compares women with the same type and stage of breast cancer to women in the overall population. For example, if the 5-year relative survival rate for a specific stage of breast cancer is 90%, it means that women who have that cancer are, on average, about 90% as likely as women who dont have that cancer to live for at least 5 years after being diagnosed.

The American Cancer Society relies on information from the SEER* database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for breast cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

(Based on women diagnosed with triple-negative breast cancer between 2010 and 2015.)

SEER Stage

5-year Relative Survival Rate

Localized

91%

Regional

65%

Distant

11%

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted drugs work.

If the cancer has not spread to distant sites, surgery is an option. Chemotherapy might be given first to shrink a large tumor followed by surgery. It might also be given after surgery to reduce the chances of the cancer coming back. Radiation might also be an option depending on certain features of the tumor.

Because hormone therapy and HER2 drugs are not choices for women with triple negative breast cancer, chemotherapy is often used.In cases where the cancer has spread to other parts of the body (stage IV) chemotherapy and other treatments that can be considered include PARP inhibitors, platinum chemotherapy, or immunotherapy.

For details, see Treatment of Triple-negative Breast Cancer.

See the article here:
Triple-negative Breast Cancer | Details, Diagnosis, and Signs

A man in So Paulo who has no evidence of remaining HIV after more than 15 months off antiretrovirals at least according to tests done so far may represent the first case of a functional cure without the risks of a stem cell transplant, according to a report presented today at the23rd International AIDS Conference (AIDS 2020: Virtual).

As part of a clinical trial, the 35-year-old man had two additional antiretrovirals, the integrase inhibitor dolutegravir (Tivicay) and the entry inhibitor maraviroc (Celsentri), added to his standard three-drug regimen. In addition, he received nicotinamide, a water-soluble form of niacin, or vitamin B3.

He underwent a closely monitored treatment interruption in March 2019. More than 15 months later, he continues to have undetectable HIV RNA (the form of viral genetic material measured in a typical viral load test) as well as undetectable HIV DNA (the form that largely makes up the viral reservoir).

But experts caution against reading too much into this case, as it involved only a single individual and extensive testing for traces of HIV at various sites in the man's body have not yet been carried out.

"The fact that it's a single case suggests that this may not be real," Dr Steven Deeks of the University of California in San Francisco told aidsmap. "We know that some people can achieve what appears to be remission with antiretroviral drugs alone. This may simply be a person who got lucky with antiretrovirals."

So far, two people appear to have been cured of HIV. Timothy Ray Brown, formerly known as the Berlin Patient, has had no evidence of replication-competent HIV anywhere in his body for more than 13 years. The second man, dubbed the London Patient, still has no detectable virus as he approaches three years off antiretroviral therapy (ART).

Both men received bone marrow transplants to treat leukaemia or lymphoma using stem cells from a donor with a rare genetic mutation known as CCR5-delta-32, which results in missing CCR5 co-receptors on T cells, the gateway most types of HIV use to infect cells. Before the transplants, they received chemotherapy to kill off their cancerous immune cells, essentially allowing the donor stem cells to rebuild a new HIV-resistant immune system.

But this procedure is far too dangerous for people whose lives are not already threatened by advanced cancer. What's more, it requires intensive medical intervention, is extremely expensive and could probably not be scaled up enough to make it feasible for the millions of people living with HIV worldwide.

This has led researchers to ask whether the right combination of medications could offer a safer and less expensive path to long-term remission or ultimately a cure.

Dr Ricardo Diaz of the University of So Paulo in Brazil, Dr Andrea Savarino of the Italian Institute of Health in Rome and their team conducted a clinical trial known as SPARC-7 to evaluate multiple interventions aimed at reducing the size of the HIV reservoir.

This reservoir is comprised of latent HIV integrated into inactive host cells, primarily T cells. Antiretrovirals cannot reach this hidden virus, but if treatment stops and the cells become reactivated, they can once again begin churning out new copies of the virus.

The study enrolled HIV-positive adults who were on their first antiretroviral regimen, had viral suppression for more than two years and had never had a CD4 count below 350 cells/mm3.

Five of the participants added dolutegravir, maraviroc and 500mg twice daily of nicotinamide to their original three-drug antiretroviral regimen for 48 weeks. They then reverted back to standard ART and finally underwent an analytical treatment interruption, in which viral load and other parameters are closely monitored.

As Savarino explained in an interview with aidsmap prior to the conference (watch above), nicotinamide was chosen because it appears to fight HIV by multiple mechanisms. Available as an inexpensive oral supplement, nicotinamide is being studied as a cancer treatment because of its immune-boosting properties. It helps prevent exhausted T cells from committing suicide (apoptosis) by inhibiting the activity of enzymes called PARPs that repair broken DNA. It may also act as a histone deacetylase (HDAC) inhibitor that keeps T cells out of a latent state. Maraviroc, too, may act as a latency-reversing agent in addition to its better-known effect of blocking HIV entry into cells.

The Brazilian who remains in remission was diagnosed with HIV in October 2012, at which time he had a lowest-ever CD4 cell count (372 cells/mm3) and viral load (over 20,000 copies/ml) characteristic of chronic infection. Two months later, he started treatment with efavirenz (Sustiva), zidovudine (AZT) and lamivudine (3TC), substituting tenofovir disoproxil fumarate (TDF) for zidovudine in 2014.

The man enrolled in the clinical trial in September 2015 and started on the intensified ART regimen plus nicotinamide. Among the 30 participants receiving various investigational regimens in the study, he was the only one who experienced low-level viral blips during his experimental treatment (at weeks 16 and 24), but his viral load thereafter remained undetectable.

Halting of the function or replication of a virus. In HIV, optimal viral suppression is measured as the reduction of viral load (HIV RNA) to undetectable levels and is the goal of antiretroviral therapy.

Taking a planned break from HIV treatment, sometimes known as a drugs holiday. As this has been shown to lead to worse outcomes, treatment interruptions are not recommended.

The disappearance of signs and symptoms of a disease, usually in response to treatment. The term is often used in relation to cancer, indicating that there is no evidence of disease, although the possibility of cancer remaining in the body cannot be ruled out. In HIV, remission is an alternative term for functional cure. A sustained ART-free remission would boost the immune system to induce long-term control of HIV, allowing a person living with HIV to maintain an undetectable viral load without daily medication.

The HIV reservoir is a group of cells that are infected with HIV but have not produced new HIV (latent stage of infection) for many months or years. Latent HIV reservoirs are established during the earliest stage of HIV infection. Although antiretroviral therapycan reduce the level of HIV in the blood to an undetectable level, latent reservoirs of HIV continue to survive (a phenomenon called residual inflammation). Latently infected cells may be reawakened to begin actively reproducing HIV virions if antiretroviral therapy is stopped.

After completing 48 weeks on this combination, he returned to his prior three-drug regimen, later swapping out efavirenz for nevirapine (Viramune) and ultimately dolutegravir. Throughout, he maintained viral suppression.

In March 2019, he started an analytical treatment interruption, stopping his antiretroviral therapy under medical supervision. Today, his viral load remains undetectable according to HIV RNA blood tests done every three weeks. His last test was on 22 June 2020, meaning he has maintained viral suppression for more than 65 weeks off antiretrovirals.

The man's CD4 cells were generally stable while on the experimental intensified regimen, rose after returning to standard three-drug therapy and then dropped after starting the treatment interruption.

Various markers of CD8 cell activation the type of T cells that fight HIV declined after starting the intensified regimen and remained below the baseline level.

Looking at other parameters can give clues about whether HIV remains present but under control or has truly been eliminated.

The man's HIV DNA level in peripheral blood immune cells rose after starting the experimental regimen suggesting the treatment may have reactivated latent reservoir cells but then fell to an undetectable level after he resumed standard ART. It has remained undetectable during the treatment interruption.

HIV DNA in the man's gut biopsy samples declined while he was on the intensified regimen. Further analysis of HIV in gut tissue, lymph nodes and other sites as Timothy Brown has undergone will be needed to show whether the man is in fact functionally cured. However, Savarino told aidsmap that these more invasive tests have been put on hold due to COVID-19 restrictions on health services in Brazil.

"Four other individuals treated with the same intensified regimen did not maintain viral suppression."

The presence of HIV antibodies indicates that, even while on treatment, enough of the virus remains to stimulate ongoing antibody production. In this case, the man's antibody level declined steadily while he was on the experimental regimen and continued to fall after he resumed three-drug therapy. During the treatment interruption, he maintained a very low antibody level low enough that a rapid antibody test became negative.

Importantly, Savarino told aidsmap, four other individuals treated with the same intensified regimen did not maintain viral suppression.

Speaking at a media briefing, conference co-chair Dr Anton Pozniak of Chelsea and Westminster Hospital recalled that we have heard of many other potential HIV cures before including the famed Mississippi baby, who maintained viral suppression off antiretrovirals for more than two years before her virus rebounded but so far these have mostly ended in disappointment.

Deeks urged caution about "overinterpreting" the findings from this case, which does not suggest any interventions that people living with HIV should undertake on their own at this time. In particular, people should not start taking nicotinamide or niacin, which can cause an uncomfortable flushing side effect at high doses.

"I would certainly encourage people to not jump on this. This may not be real and it could actually cause harm," he said. "I would not encourage anyone to run out to the local health food store and get this drug, and dont stop taking antiretrovirals."

More here:
Brazilian man in long-term HIV remission without a stem cell transplant - aidsmap

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The Company plans to initiate clinical investigation of FT819 for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development.”

FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory at MSK, the Company incorporated several first-of-kind features into FT819 including:

The multi-center Phase 1 clinical trial of FT819 is designed to determine the maximum tolerated dose of FT819 and assess its safety and clinical activity in up to 297 adult patients across three types of B-cell malignancies (CLL, ALL, and NHL). Each indication will enroll independently and evaluate three dose-escalating treatment regimens: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819.

At the American Association for Cancer Research (AACR) Virtual 2020 Meeting, the Company presented preclinical data demonstrating FT819 is comprised of CD8a T cells with uniform 1XX CAR expression and complete elimination of endogenous TCR expression. Additionally, data from functional assessments showed FT819 has antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines that is comparable to that of healthy donor-derived CAR T cells, and persists and maintains tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia.

Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452 pursuant to its license agreement with MSK1, which patent covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

1 Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

About Fate Therapeutics’ iPSC Product Platform The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates and clinical studies, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, the therapeutic potential of the Company’s product candidates including FT819, and the Company’s clinical development strategy for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any ongoing or future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT819 may not be replicated in ongoing or future clinical trials or studies, and the risk that FT819 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

Go here to see the original:
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy | 2020-07-09 | Press Releases - Stockhouse

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The Company plans to initiateclinical investigation of FT819for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development.

FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory at MSK, the Company incorporated several first-of-kind features into FT819 including:

The multi-center Phase 1 clinical trial of FT819 is designed to determine the maximum tolerated dose of FT819 and assess its safety and clinical activity in up to 297 adult patients across three types of B-cell malignancies (CLL, ALL, and NHL). Each indication will enroll independently and evaluate three dose-escalating treatment regimens: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819.

At the American Association for Cancer Research (AACR) Virtual 2020 Meeting, the Company presented preclinical data demonstrating FT819 is comprised of CD8 T cells with uniform 1XX CAR expression and complete elimination of endogenous TCR expression. Additionally, data from functional assessments showed FT819 has antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines that is comparable to that of healthy donor-derived CAR T cells, and persists and maintains tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia.

Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452 pursuant to its license agreement with MSK1, which patent covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

1 Fate Therapeutics haslicensedintellectual propertyfrom MSK on which Dr. Sadelain is aninventor.As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates and clinical studies, the Companys progress, plans and timelines for the clinical investigation of its product candidates, the therapeutic potential of the Companys product candidates including FT819, and the Companys clinical development strategy for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any ongoing or future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT819 may not be replicated in ongoing or future clinical trials or studies, and the risk that FT819 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

See original here:
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy - GlobeNewswire

Los Angeles, United State: QY Research recently published a research report titled, Global Stem Cell Cryopreservation Equipment Market Research Report 2020 The research report is collated on the basis of historic and forecast data derived by using primary and secondary methodologies by researchers. The global Stem Cell Cryopreservation Equipment market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The Stem Cell Cryopreservation Equipment report clearly explains the trajectory this market will take in the forecast years.

The Stem Cell Cryopreservation Equipment research report has presented an analysis of various factors influencing the markets current growth. Drivers, restraints, and trends are elaborated to understand their positive or negative effects. This Stem Cell Cryopreservation Equipment report section is aimed at providing readers with a thorough information about the potential scope of various applications and segments. These estimates are based on the current trends and historic milestones.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.qyresearch.com/sample-form/form/1761403/covid-19-impact-on-stem-cell-cryopreservation-equipment-market

This section of the Stem Cell Cryopreservation Equipment report offers a thorough and comprehensive information about the various manufacturers in the market. The major manufacturers covered in the report hold significant share that demands a microscopic look. It provides vital information about various strategies implemented by these manufacturers to combat competition and expand their footprint in the Stem Cell Cryopreservation Equipment market. It also surveys the current trends adopted by the manufacturers to innovate their product for the future. This Stem Cell Cryopreservation Equipment report is structured in such a way so as to help the reader understand the market and make business decisions accordingly.

Key Players Mentioned in the Global Stem Cell Cryopreservation Equipment Market Research Report:

Chart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol

Global Stem Cell Cryopreservation Equipment Market Segmentation by Product:Liquid PhaseVapor Phase

Global Stem Cell Cryopreservation Equipment Market Segmentation by Application:Cord Blood Stem Cell CryopreservationOther Stem Cell Cryopreservation

The Stem Cell Cryopreservation Equipment Market research report briefs on segments such as product type and end users. The product type segment gives an understanding about various products available in the Stem Cell Cryopreservation Equipment market. It also gives information on what is the scope and potential of each product. Also, the segment presents an elaborate information on end users. Understanding end users is of utmost importance as it aids in identifying marketable areas.

Key questions answered in the report: What is the growth potential of the Stem Cell Cryopreservation Equipment market? Which product segment will grab a lions share? Which regional market will emerge as a frontrunner in coming years? Which application segment will grow at a robust rate? What are the growth opportunities that may emerge in Stem Cell Cryopreservation Equipment industry in the years to come? What are the key challenges that the global Stem Cell Cryopreservation Equipment market may face in future? Which are the leading companies in the global Stem Cell Cryopreservation Equipment market? Which are the key trends positively impacting the market growth? Which are the growth strategies considered by the players to sustain hold in the global Stem Cell Cryopreservation Equipment market?

Request for customization in Report:@https://www.qyresearch.com/customize-request/form/1761403/covid-19-impact-on-stem-cell-cryopreservation-equipment-market

Table od Content:1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Stem Cell Cryopreservation Equipment Industry1.7 COVID-19 Impact: Stem Cell Cryopreservation Equipment Market Trends

2 Global Stem Cell Cryopreservation Equipment Quarterly Market Size Analysis2.1 Stem Cell Cryopreservation Equipment Business Impact Assessment COVID-192.1.1 Global Stem Cell Cryopreservation Equipment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Stem Cell Cryopreservation Equipment Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Stem Cell Cryopreservation Equipment Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges

3 Quarterly Competitive Assessment, 20203.1 Global Stem Cell Cryopreservation Equipment Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Stem Cell Cryopreservation Equipment Factory Price by Manufacturers3.3 Location of Key Manufacturers Stem Cell Cryopreservation Equipment Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Stem Cell Cryopreservation Equipment Market3.5 Key Manufacturers Stem Cell Cryopreservation Equipment Product Offered3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Stem Cell Cryopreservation Equipment Segments, By Type4.1 Introduction1.4.1 Liquid Phase1.4.2 Vapor Phase4.2 By Type, Global Stem Cell Cryopreservation Equipment Market Size, 2019-20214.2.1 By Type, Global Stem Cell Cryopreservation Equipment Market Size by Type, 2020-20214.2.2 By Type, Global Stem Cell Cryopreservation Equipment Price, 2020-2021

5 Impact of Covid-19 on Stem Cell Cryopreservation Equipment Segments, By Application5.1 Overview5.5.1 Cord Blood Stem Cell Cryopreservation5.5.2 Other Stem Cell Cryopreservation5.2 By Application, Global Stem Cell Cryopreservation Equipment Market Size, 2019-20215.2.1 By Application, Global Stem Cell Cryopreservation Equipment Market Size by Application, 2019-20215.2.2 By Application, Global Stem Cell Cryopreservation Equipment Price, 2020-2021

6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa

7 Company Profiles7.1 Chart7.1.1 Chart Business Overview7.1.2 Chart Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.1.3 Chart Stem Cell Cryopreservation Equipment Product Introduction7.1.4 Chart Response to COVID-19 and Related Developments7.2 Worthington Industries7.2.1 Worthington Industries Business Overview7.2.2 Worthington Industries Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.2.3 Worthington Industries Stem Cell Cryopreservation Equipment Product Introduction7.2.4 Worthington Industries Response to COVID-19 and Related Developments7.3 Cesca Therapeutics7.3.1 Cesca Therapeutics Business Overview7.3.2 Cesca Therapeutics Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.3.3 Cesca Therapeutics Stem Cell Cryopreservation Equipment Product Introduction7.3.4 Cesca Therapeutics Response to COVID-19 and Related Developments7.4 Shengjie Cryogenic Equipment7.4.1 Shengjie Cryogenic Equipment Business Overview7.4.2 Shengjie Cryogenic Equipment Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.4.3 Shengjie Cryogenic Equipment Stem Cell Cryopreservation Equipment Product Introduction7.4.4 Shengjie Cryogenic Equipment Response to COVID-19 and Related Developments7.5 Sichuan Mountain Vertical7.5.1 Sichuan Mountain Vertical Business Overview7.5.2 Sichuan Mountain Vertical Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.5.3 Sichuan Mountain Vertical Stem Cell Cryopreservation Equipment Product Introduction7.5.4 Sichuan Mountain Vertical Response to COVID-19 and Related Developments7.6 Qingdao Beol7.6.1 Qingdao Beol Business Overview7.6.2 Qingdao Beol Stem Cell Cryopreservation Equipment Quarterly Production and Revenue, 20207.6.3 Qingdao Beol Stem Cell Cryopreservation Equipment Product Introduction7.6.4 Qingdao Beol Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis8.1 Stem Cell Cryopreservation Equipment Supply Chain Analysis8.1.1 Stem Cell Cryopreservation Equipment Supply Chain Analysis8.1.2 Covid-19 Impact on Stem Cell Cryopreservation Equipment Supply Chain8.2 Distribution Channels Analysis8.2.1 Stem Cell Cryopreservation Equipment Distribution Channels8.2.2 Covid-19 Impact on Stem Cell Cryopreservation Equipment Distribution Channels8.2.3 Stem Cell Cryopreservation Equipment Distributors8.3 Stem Cell Cryopreservation Equipment Customers

9 Key Findings

10 Appendix10.1 About Us10.2 Disclaimer

About Us:QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Continue reading here:
Stem Cell Cryopreservation Equipment Market Size, Growth Trends, Top Players, Application Potential and Forecast to 2026| Chart, Worthington...

SYDNEY, N.S.

Its National Blood Donor Week in Canada, but some Cape Breton Regional Municipality residents are feeling left out.

I was so surprised when the clinic closed here several years ago, said Maggie Lynne MacNeil of Sydney, who made it a priority to donate blood when the service was here. It was a motor vehicle accident involving her husband seven years agothat opened her eyes to the importance of blood donation.

MacNeil said shes grateful Canadian Blood Collection Services provides this important service and has contacted them to find out if a clinic might reopen in the municipality.

Monetary donations are important everywhere and can do a lot of good, she said. Blood can save lives. We lost it, but I think if it was brought back people would support it more than ever. There's no way we can donate blood here. That doesn't even make sense."

Rene Horton, spokesperson for Canadian Blood Services, said they do receive questions, comments and requests to return (the service) to Sydney.

We receive approximately five or so per year, she said.

However, a return to Sydney is not on the horizon, said Peter MacDonald, director of donor relations for the Atlantic region.

MacDonald said as of now, there are enough events in their clinic plan to meet hospital demand.

Id never say never, but theres no immediate plans to reopen the site, he said.

The blood collection clinic which was located on Grand Lake Road in Sydney closed in May 2015.

MacDonald said the decision to close was due to a decline in hospital demand for blood and blood products in the area.

Donations wasnt the issue, he said. We had certainly dedicated donors in Sydney and all the CBRM, too, he said.

There is currently no place in the Cape Breton Regional Municipality to donate blood. The nearest place to make a donation is the mobile clinic that visits Port Hawkesbury four or five times a year. Those two-day visits have a 173-unit target and consistently meets and exceeds the target.

This is National Blood Donor Week and Sunday will mark National Blood Donor Day.

The goal for Nova Scotia is 667 donations and as of Thursday, the Canadian Blood Collection Services needed 204 blood donations for the rest of June to meet the target. Those appointments were already booked to meet that goal.

Less than four per cent of the population of Canada are active donors. There are more than 20,000 active blood donors in Nova Scotia.

One donation of blood could potentially save three lives, as three components are drawn from each:plasma which can be frozen and last for up to a year, red cells which have a 42-day shelf life and platelets which only last for seven days.

There is also always a need for O negative blood, the universal blood type.

MacDonald said there are other ways Cape Bretoners can help including by joining the stem cell registry online at http://www.blood.ca. Participants are sent a kit, swab the inside of their cheek and then return the swab. The results are placed on the stem cell registry.

The need to grow the registry is there, particularly with males 17-35. As well, the registry is in need of ethnic diversity. Currently, the makeup of the registry doesnt match the population in Canada as the patient population continues to become more diverse.

MacDonald said they are grateful to those in Cape Breton who have given blood and continue to do so at mobile clinics.

I would also assure readers of the Cape Breton Post that the fact that we dont collect there doesnt mean that hospitals there dont receive all the help needed, he said.

Theres no risk that hospitals in Cape Breton dont receive blood and blood products when they need it.

Meanwhile, MacDonald said the COVID-19 crisis has impacted the blood service in a few ways. For example, since mid-March, some mobile clinics have been shut down due to the pandemic.

Even with the loss of capacity, we were still able to meet hospital demand, he said, adding demand decreased due to the pandemic as well because elective surgeries were cancelled, there were fewer traumas as less people were moving around and on highways, for example.

As the province begins to reopen and elective surgeries are rescheduled, hospital demand will begin to increase.

Its starting to get back to pre-COVID levels, he said. Fortunately some of those sites not available for mobiles are now reopening.

The full schedule for mobile units can be viewed at http://www.blood.ca and people can download the donate blood app.

RELATED:

Excerpt from:
It's National Blood Donor Week, but nowhere to donate in Cape Breton Regional Municipality - The Telegram

LOUISVILLE, Ky. The American Heart Association is investing nearly $17 million to fund a two-year research initiative, ENACT (End Nicotine Addiction in Children and Teens), led by a national network of scientists focusing on the health impacts of e-cigarettes and other nicotine delivery systems on youth and young adults.

As part of this network, researchers at the University of Louisville Christina Lee Brown Envirome Institute will conduct studies to better understand youth vaping. Institute researcher Joy Hart, professor in the UofL Department of Communication, will lead a team engaging local youth to learn about what drives youth to use e-cigarettes, the health effects of this use and how to motivate young people to stop using these products.

This investment is the latest in a multipronged, ongoing commitment announced last fall by the American Heart Association to fight the growing epidemic of youth vaping.

E-cigarettes are being marketed as a healthy option to traditional cigarettes, but no one knows if vaping is safe in the long run because e-cigarettes havent been around long enough to be studied deeply. Some diseases can take years and even decades to develop, so there is more work needed to fully understand all the dangers, said Dr. Robert A. Harrington, AHA president, Arthur L. Bloomfield professor of medicine and chair of the department of medicine at Stanford University. Theres certainly plenty of indication theyre harmful for growing minds and bodies because we know e-cigarettes contain nicotine and we know the harmful effects of nicotine, but its important we grow that overall body of scientific evidence.

Harrington said theres a sense of urgency because, at a time when regular cigarette smoking has reached an all-time low, young people are turning to e-cigarettes at epidemic proportions with nearly one in four high school students reportedly vaping. Thats why these research projects will be high-impact and fast tracked, only two years in length and funded at levels among the highest individual grants awarded in the associations history. The initiative is designed to produce turnkey programs to support youth as well as provide clear evidence to inform policy decisions.

The UofL research project is part of the Rapidly Advancing Discovery to Arrest the Outbreak of Youth Vaping Center (VAPERACE) at Boston University. Hart will spearhead community outreach activities and will work with other center investigators to understand the health impact of vaping on youth and to develop new approaches to vaping cessation. The research team includes Kandi Walker, Rachel Keith and Aruni Bhatnagar, director of the Envirome Institute.

Tobacco use causes health issues for many Kentuckians, and is particularly concerning in young people. We are pleased that researchers in the UofL Christina Lee Brown Envirome Institute will contribute to this significant effort by the American Heart Association and hopefully reduce the negative health effects of tobacco use on the next generation, said Neeli Bendapudi, president of the University of Louisville.

Studying vaping among youth has always been important. It became even more important with widespread lung illness among young people, Bhatnagar said. Now, in context of the COVID-19 pandemic, it appears that those who use nicotine may be at greater risk of serious COVID-19 illness.

In addition to UofL, VAPERACE at Boston University includes projects by Johns Hopkins University and Stanford University. The projects supported by the center include: basic research using human-induced pluripotent stem cell samples to test e-cigarette component toxicity, mobile health technology to measure the physiological cardiovascular impacts of e-cigarettes on youth in real-world settings and a virtual reality and text messaging-delivered e-cigarette cessation program for youth developed by combining social media methods with focus groups.

Two additional projects funded by the AHA as part of the network are based at Ohio State University and Yale University. Overall, network researchers will work to identify the biological impacts of vaping on multiple organ systems (heart, brain, lungs, vascular system, etc.), behavioral factors and specific social influencers of health to reverse these trends.

The rapid pace of e-cigarette products entering the market and targeting our youth requires an ambitious, aggressive approach beyond the incremental pace achieved through traditional research mechanisms. Policymakers, regulators, medical professionals and schools are looking to enact strategies, policies and solutions but theres inadequate evidence to inform these efforts, Harrington said. The American Heart Association is proud to be on the forefront of bringing together some of the best minds in their fields to conduct the research, development and testing to bring bold and innovative results to address the growing epidemic of youth vaping in our commitment of longer, healthier lives for all.

See original here:
UofL researchers to study health impacts of vaping, nicotine on youth - The Lane Report

THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- Treatment of childhood cancer is a success story, particularly for acute lymphoblastic leukemia (ALL). More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy. However, the remaining 10% have resistant or reoccurring leukemia and require alternative treatment regimens. One of the most powerful leukemia therapies is hematopoietic stem cell transplantation from a donor (allogeneic HSCT). Approximately 50-80% of pediatric ALL patients that receive allogeneic HSCT are cured, 20% experience leukemic reoccurrence (relapse), and 10% die from complications.

Allogeneic HSCT is a multistep procedure:

For high-risk leukemia, the gold standard conditioning procedure is a combination of total body irradiation (TBI) and high dose chemotherapy. This approach is very effective in controlling leukemia in the conditioning step, but patients may experience highly negative consequences of this procedure later in life: sterility, growth retardation, lung problems, and secondary cancer.

Therefore, a large consortium of pediatric transplant experts initiated a global study to investigate whether chemotherapy-based conditioning could substitute TBI. The study is called FORUM (For Omitting Radiation Under Majority Age) and had to be stopped because chemotherapy-based conditioning had significantly poorer outcomes (i.e., lower overall survival rates) than the combination of TBI and chemotherapy. The researchers will now perform prospective monitoring to better define the advantages and limitations of various conditioning approaches.

Presenter:Dr Christina PetersAffiliation:Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna, AustriaAbstract:#S102 TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

Embargo: Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information click here.

Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

Visit link:
EHA25Virtual: Combined Irradiation and Chemotherapy Better Prepares Children for Stem Cell Transplantation than Chemotherapy Alone - P&T Community

Stem Cell Assay Market Overview

The Stem Cell Assay market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Stem Cell Assay market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Stem Cell Assay) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=JLN&utm_medium=005

Leading Stem Cell Assay manufacturers/companies operating at both regional and global levels:

Stem Cell Assay Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Stem Cell Assay market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Stem Cell Assay market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Stem Cell Assay Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Stem Cell Assay market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=JLN&utm_medium=005

Stem Cell Assay Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Stem Cell Assay market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Stem Cell Assay Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Assay Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Assay Market, By Deployment Model

5.1 Overview

6 Stem Cell Assay Market, By Solution

6.1 Overview

7 Stem Cell Assay Market, By Vertical

7.1 Overview

8 Stem Cell Assay Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Assay Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=JLN&utm_medium=005

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Single-use Bioreactors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Assay Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Sterile Filtration Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See more here:
Stem Cell Assay Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - Jewish Life News

Stem Cell Therapy Market Overview

The Stem Cell Therapy market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Stem Cell Therapy market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Stem Cell Therapy) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=JLN&utm_medium=005

Leading Stem Cell Therapy manufacturers/companies operating at both regional and global levels:

Stem Cell Therapy Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Stem Cell Therapy market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Stem Cell Therapy market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Stem Cell Therapy Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Stem Cell Therapy market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=JLN&utm_medium=005

Stem Cell Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Stem Cell Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=JLN&utm_medium=005

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Influenza Diagnostics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read this article:
Stem Cell Therapy Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - Jewish Life News